Skip Content
You are currently on the new version of our website. Access the old version .

Medical Sciences, Volume 7, Issue 10

2019 October - 5 articles

Cover Story: Esophageal cancer (EC) is among the most frequent and deadly cancers around the world. Fortunately, two targeted therapies and an immunotherapy agent have been recently approved by the FDA for metastatic ECs. PD1 inhibitor pembrolizumab has received approvals for later line treatment of both types of EC: squamous cell carcinoma and adenocarcinoma. Ramucirumab, an antibody targeting VEGF and HER2/neu receptors, has been approved for refractory adenocarcinoma, while the anti-HER2 antibody trastuzumab has been approved as front-line treatment for the 20% of cases that are HER2-positive. Although these therapies have improved survival for PDL1- and-HER2/neu positive patients, the survival rates remain low for metastatic EC, necessitating the development of further targeted treatment options. View this paper.
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (5)

  • Review
  • Open Access
37 Citations
5,862 Views
12 Pages

Targeted Therapies and Immunotherapies in the Treatment of Esophageal Cancers

  • Adam Barsouk,
  • Prashanth Rawla,
  • Andreas V. Hadjinicolaou,
  • John Sukumar Aluru and
  • Alexander Barsouk

26 September 2019

Esophageal cancer (EC) is among the most frequent and deadly cancers around the world. While esophageal adenocarcinoma (EAC) has one of the fastest-growing incidences amongst cancers in the US, it also has one of the lowest survival rates due to the...

  • Review
  • Open Access
11 Citations
4,762 Views
12 Pages

23 September 2019

TRPA1, a versatile ion channel of the Transient Receptor Potential (TRP) channel family, detects a large variety of chemicals and can contribute to signal processing of other stimuli, e.g., due to its sensitivity to cytosolic calcium elevation or pho...

  • Article
  • Open Access
3 Citations
4,276 Views
9 Pages

Compliance and Treatment Outcomes of Various Regimens for Trichomoniasis in Trinidad and Tobago

  • Aruna Kumari Divakaruni,
  • Bisram Mahabir,
  • F. A. Orrett,
  • Sneha Rao Adidam,
  • Srikanth Adidam Venkata,
  • V. Chalapathi Rao Adidam and
  • Srinivas Divakaruni

20 September 2019

Trichomoniasis is the most common non-viral sexually transmitted disease (STD) globally and yet is not a reportable disease. Trichomonas vaginalis is an important source of reproductive morbidity and may increase risk of acquisition and transmission...

  • Review
  • Open Access
24 Citations
8,223 Views
7 Pages

20 September 2019

Sexual function among older men is often thought to decrease as part of normal ageing biology despite the fact that sexuality remains an important issue in the elderly. Sexual dysfunction in the aged male is likely multifactorial in nature, with the...

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Med. Sci. - ISSN 2076-3271